Studies of Avian Influenza Transmission to Humans in Egypt

Status Completed

Clinical Trial Summary

The main focus of the study is:

- To estimate seroprevalence of AI in poultry-exposed and non-exposed human populations.

- To estimate the incidence of AI in poultry-exposed and non-exposed human populations.

- To investigate risk factors associated with AI infections in occupationally-exposed poultry workers.

The secondary objectives of the study:

- To investigate patterns in transmission of AI to household contacts of AI clinical cases

- To isolate AI viruses from acute cases

- To monitor the pathogenicity and disease severity of AI viruses causing human infections

Clinical Trial Description

This 4-year prospective cohort study to compare individuals with occupational exposure to poultry with non-poultry exposed adult controls for evidence of incident and previous infections with AI viruses. At the start of this study, study staff will obtain informed consent, and a blood sample will be obtained from study volunteers to establish baseline levels of antibodies against avian influenza types H4-H12. Subjects will be interviewed regarding their exposures, medical history, and behaviors using a close-ended questionnaire specifically tailored for this study. After one year, study subjects will be interviewed again to note any changes in exposure variables. At this time, another blood sample will be obtained and tested for any changes in antibodies' levels. The same procedures will be repeated at the final visit after another year. Exposed individuals will be selected from rural areas where poultry is commonly raised. Non-exposed controls will be selected from urban neighborhoods in Cairo. ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01150552
Study type	Observational
Source	St. Jude Children's Research Hospital
Contact
Status	Completed
Phase	N/A
Start date	June 2010
Completion date	May 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01698060` - Immunogenicity of ND1.1 by Delivery Directly to the Ileum	Phase 1
Completed	`NCT02213354` - H7N9 Mix and Match With MF59 in Healthy Elderly Persons	Phase 2
Completed	`NCT02295813` - Safety and Pharmacokinetics Study of FBF001	Phase 1
Completed	`NCT00561184` - Safety and Immunogenicity of a Booster Dose of -H5N1 Influenza Vaccine	Phase 2
Completed	`NCT02921997` - H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses	Phase 2
Completed	`NCT03682120` - Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza	Phase 2
Completed	`NCT00895544` - Immunogenicity and Safety Study of a Single Prime-Boost Vaccination Schedule With a H5N1 Influenza Vaccine in Adults	Phase 1/Phase 2
Completed	`NCT02251288` - A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine	Phase 1
Completed	`NCT02612909` - A Safety and Immunogenicity Study of IVACFLU-A/H5N1	Phase 2/Phase 3
Completed	`NCT02229357` - Evaluation of Priming Effects by PLAI Vaccine on the Subsequent Response to Inactivated H5N1 Vaccine	Phase 2
Completed	`NCT03472976` - H5N1 With or Without Topical Aldara in Healthy Adults	Phase 1
Completed	`NCT01897701` - A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1	Phase 1
Completed	`NCT01107262` - Avian Influenza Studies In Lebanon	N/A
Completed	`NCT02839330` - A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age	Phase 3
Completed	`NCT03014310` - H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology	Phase 1
Completed	`NCT00298233` - High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza	Phase 2
Completed	`NCT03318315` - Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4	Phase 2
Completed	`NCT03312231` - Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly	Phase 2
Completed	`NCT03738241` - 2017 A/H7N9 IIV Revaccination	Phase 2
Completed	`NCT03589807` - 2013/2017 H7N9 Prime-Boost Interval	Phase 2